S M Swain

Summary

Publications

  1. ncbi Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
    S M Swain
    Comprehensive Breast Center, Washington, DC 20015 2034, USA
    J Clin Oncol 15:1318-32. 1997
  2. ncbi Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
    S M Swain
    Comprehensive Breast Center, Washington, DC 20015 2034, USA
    J Clin Oncol 15:1333-40. 1997

Detail Information

Publications2

  1. ncbi Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
    S M Swain
    Comprehensive Breast Center, Washington, DC 20015 2034, USA
    J Clin Oncol 15:1318-32. 1997
    ..To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast cancer...
  2. ncbi Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
    S M Swain
    Comprehensive Breast Center, Washington, DC 20015 2034, USA
    J Clin Oncol 15:1333-40. 1997
    ..To assess whether dexrazoxane (DZR) given after a cumulative doxorubicin dose of 300 mg/m2 confers cardioprotection in patients with advanced breast cancer treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC)...